Went public 10/5/00 at $14 per share
Shares Outstanding:23.8 million shares
Underwriters: Lehman Brothers/CIBC World Markets/SG Cowen Securities/Fidelity Capital Markets
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Brobeck Phleger & Harrison LLP
Auditor: Ernst & Young LLP
Develops new pharmaceuticals through the application of “combinatorial biosynthesis”, the generation of novel analogs of natural products by genetic engineering of biosynthetic pathways.
Walden International Investment Group
Goldman, Sachs & Co.
Burr, Egan, Deleage & Co.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 04/01/1996 2 Expansion 3000.0
2 01/03/1997 5 Early Stage 2399.9
3 04/02/1998 8 Expansion 15000.1
4 03/24/2000 8 Expansion 24930.0
(Data in $ millions)
Total Revenues: $5.3
Net Income: -4.4